In The Know: Questions on our mind...the future of bladder cancer treatment

A new round of research has begun with key opinion leaders (KOLs) from the US and Europe to explore the future of bladder cancer therapies. Interviews with leading oncologists will cover the unmet needs that exist in current treatment strategies and what role innovative new therapies  are expected to play in the coming years. With the aim of learning how diagnosis and treatment landscapes will evolve in the near future, the research will follow the key lines of inquiry set out below.

Bladder cancer key intelligence areas -- lines of inquiry

  1. What are the unmet needs in the treatment of bladder cancer? Can diagnosis be improved?

  2. Have there been any changes in how patient groups are treated over the last 12 months? How do KOLs view the conventional treatment options of surgery, BCG vaccination and chemotherapy for early- and late-stage disease?

  3. Over the last 12 months, what were the key changes in the use and prescribing of the PD-1/PD-L1 immune checkpoint inhibitors in bladder cancer?

  4. Which immuno-oncology (IO) strategies do KOLs believe hold the most promise in bladder cancer; anti-PD-1 (e.g. pembrolizumab, nivolumab), anti-PD-L1 (e.g. avelumab, durvalumab, atezolizumab), anti-CTLA-4 (e.g. ipilimumab, tremelimumab), IDO1 inhibitor (epacadostat) or combinations therein?

  5. What do KOLs think about next-generation IO approaches, including oncolytic virus therapies and cytokine-based treatments?

  6. Are KOLs excited about late-stage programmes from Eli Lilly (Cyramza), Astellas/Seattle Genetics (enfortumab vedotin), Janssen (erdafitinib) and Bayer (rogaratinib)?

  7. How do KOLs view intravesical gene therapies as a treatment strategy in patients with non-muscle invasive bladder cancer (NMIBC)?

  8. How is the treatment paradigm likely to evolve over the next three-to-five years, and what potential challenges and opportunities exist?

Submit any questions about this research here.



To read more Sponsored Story articles, click here.

Reference Articles